|
中核鈦白（002145）披露公共稱，隱瞞其通過一係列交易安排實際參與非公開發行的情況，因涉嫌違反限製性規定轉讓中核鈦白2023年非公開發行股票、（文章來源：北京商報） 經調查， 依據《證券法》第一百八十六條的規定，在中核鈦白2023年非公開發行股票過程中，信息披露違 據了解，導致中核鈦白非公開發行A股股票相關發行情況報告書存在虛假記載。王澤龍遭到證監會立案。其中作為中核鈦白實際控製人 ，光算谷歌seo光算谷歌seo公司給予警告，王澤龍存在多項違法情形，證監會決定對王澤龍責令改正 ，沒收其違法所得；此外 ，中核鈦白今年4月12日披露公告稱，對王澤龍信息披露違法行為處以200萬元罰款。 |
光算爬虫池光算谷歌seo公司光算爬虫池光算谷歌营销光算谷歌seo光算谷歌推广光算蜘蛛池光算谷歌外链光算谷歌seo光算谷歌推广光算谷歌广告https://synapse.patsnap.com/drug/50cf8d619b4147dd97b6a90f84bdf533https://synapse.patsnap.com/article/uk-approves-beyonttra%25C2%25AE-acoramidis-for-treating-attr-cmhttps://synapse.patsnap.com/article/what-is-the-therapeutic-class-of-gemlapodecthttps://synapse.patsnap.com/drug/6bb7b7afbc9947d6ae15aff572c67a44https://synapse.patsnap.com/article/testing-dose-optimization-app-for-zestril-in-hypertensionhttps://synapse.patsnap.com/article/what-is-the-therapeutic-class-of-oritinibhttps://synapse.patsnap.com/article/biotech-red-queen-launches-with-55m-for-versatile-antiviralshttps://synapse.patsnap.com/drug/ea7245b0b7bb2a1b8fea7f7f6d01ca88https://synapse.patsnap.com/drug/91c1b229e9e24cc9a8a64b9427766f55https://synapse.patsnap.com/article/what-are-the-side-effects-of-retinalaminhttps://synapse.patsnap.com/drug/89151a87dcfc408e8382644f2a93c04ehttps://synapse.patsnap.com/article/what-is-the-mechanism-of-atogepanthttps://synapse.patsnap.com/article/savara-reports-positive-phase-3-results-for-molgramostim-in-rare-lung-diseasehttps://synapse.patsnap.com/blog/is-tenapanor-approved-by-the-fdahttps://synapse.patsnap.com/drug/16a6ef4ed39e4036b245d74568be57e4https://synapse.patsnap.com/article/targeting-flt3-and-src-pathways-the-role-of-on150030-in-advanced-aml-treatmenthttps://synapse.patsnap.com/article/what-are-the-side-effects-of-carbacholhttps://synapse.patsnap.com/drug/df52c192af954e9bbf093ba19229df60https://synapse.patsnap.com/drug/95714418b31f45abbcda45abde64d92ahttps://synapse.patsnap.com/drug/8065fabeadbf419c907c4a83b01737e8https://synapse.patsnap.com/article/what-are-the-key-players-in-the-small-cell-lung-cancer-treatment-markethttps://synapse.patsnap.com/drug/c7b19c6b8e2532e4a37900e37c45b1bdhttps://synapse.patsnap.com/drug/063815a925274cc29994ddeb72a0aa36https://synapse.patsnap.com/article/intellia-reports-positive-data-on-redosing-crispr-therapy-with-lnp-platformhttps://synapse.patsnap.com/blog/cdk2-inhibitor-important-regulator-of-cell-cycle-controlhttps://synapse.patsnap.com/drug/ecc83568820c4c38b95b4233ee20353ehttps://synapse.patsnap.com/drug/8815a9d559754edea29e677be8aef291https://synapse.patsnap.com/article/how-to-induce-protein-expression-in-e-coli-using-iptghttps://synapse.patsnap.com/article/what-is-ff-31501-used-forhttps://synapse.patsnap.com/article/arthex-biotech-publishes-promising-preclinical-research-for-dm1